| Literature DB >> 35053256 |
Tibor Stark1,2, Fabio Arturo Iannotti3, Serena Di Martino4, Martina Di Bartolomeo5, Jana Ruda-Kucerova1, Fabiana Piscitelli3, Carsten T Wotjak6, Claudio D'Addario5, Filippo Drago4, Vincenzo Di Marzo3,7, Vincenzo Micale4.
Abstract
In agreement with the neurodevelopmental hypothesis of schizophrenia, prenatal exposure of Sprague-Dawley rats to the antimitotic agent methylazoxymethanol acetate (MAM) at gestational day 17 produces long-lasting behavioral alterations such as social withdrawal and cognitive impairment in adulthood, mimicking a schizophrenia-like phenotype. These abnormalities were preceded at neonatal age both by the delayed appearance of neonatal reflexes, an index of impaired brain maturation, and by higher 2-arachidonoylglycerol (2-AG) brain levels. Schizophrenia-like deficits were reversed by early treatment [from postnatal day (PND) 2 to PND 8] with the CB1 antagonist/inverse agonist AM251 (0.5 mg/kg/day). By contrast, early CB1 blockade affected the behavioral performance of control rats which was paralleled by enhanced 2-AG content in the prefrontal cortex (PFC). These results suggest that prenatal MAM insult leads to premorbid anomalies at neonatal age via altered tone of the endocannabinoid system, which may be considered as an early marker preceding the development of schizophrenia-like alterations in adulthood.Entities:
Keywords: 2-arachidonoylglycerol (2-AG); AM251; MAM model; cannabinoid CB1 receptor; endocannabinoid system; schizophrenia
Mesh:
Substances:
Year: 2022 PMID: 35053256 PMCID: PMC8773886 DOI: 10.3390/biom12010108
Source DB: PubMed Journal: Biomolecules ISSN: 2218-273X
Figure 1Experimental design that was used to investigate the effects of early pharmacological cannabinoid CB1 receptor blockade in MAM model of schizophrenia. Experiment 1: pregnant rats were exposed to methylazoxymethanol (MAM) acetate (22 mg/kg; i.p.) or saline (CNT: 1 mg/kg; i.p.) on gestational day (GD) 17. The resulting male offspring were subjected to behavioral tests at two different time points [neonatal age from postnatal day (PND) 1 to PND 11 and adulthood from PND 100], followed by neurochemical analysis. Experiment 2: pregnant rats were exposed to MAM acetate (22 mg/kg; i.p.) or saline (CNT: 1 mg/kg; i.p.) on GD 17. The resulting male offspring were treated from PND 2 to PND 8 with vehicle (VHC) or AM251 (0.5 mg/kg/day; s.c.). Behavioral and neurochemical analysis of the offspring were conducted at adulthood from PND 100.
Figure 2Effects of prenatal MAM exposure on neonatal behavior and endocannabinoid system (ECS) elements in rat pups. Data are presented as the mean values ±S.E.M.: (A–F) percentual cumulative appearance of each reflex on each day, per group of animals (n = 20), (G) the number of approaches towards maternal nest (nest seeking) and (H) nest exploration (n = 20/group), (I) 2-AG, PEA, OEA and (J) AEA levels, of (K) gene and (L) protein expression of ECS elements (receptors and metabolic enzymes; n = 3–5/group). * p < 0.05 vs. CNT.
Figure 3Effects of perinatal MAM exposure on the behavioral phenotype of rats that were tested (A,B) in the open field test (OFT), (C,D) in the social interaction (SI) test, and (E,F) in the novel object recognition (NOR) test at adulthood. Data are presented as means ±S.E.M. (n = 9–15). * p < 0.05 and ** p < 0.01 vs. CNT.
Figure 4Effects of early pharmacological blockade of cannabinoid CB1 receptor on MAM rats at adulthood. Data are presented as means ±S.E.M (n = 7–12) of (A,B) locomotor activity in the OFT, (C,D) social behavior in the SI, (E,F) cognitive performance in the NOR, and of (G) (n = 3–5) 2-AG content in the PFC. * p < 0.05 and *** p < 0.01vs. CNT/VHC; # p < 0.05 vs. MAM/VHC.